EGFR and head and neck squamous cell carcinoma: Moreover, NIR-PIT targeting the epidermal growth factor receptor (EGFR) using a cetuximab-IR700 conjugate was approved in Japan in September 2020 for the treatment of recurrent head and neck squamous cell carcinoma.